1
项与 Magicell-NK(Medigen Biotechnology) 相关的临床试验A Dose-Escalating Phase I Study to Determine the Safety, and Maximum Tolerated Dose/ Maximum Feasible Dose of Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection
This is a Phase I, open-label study to explore the safety profile and to find the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of Magicell-NK in subjects diagnosed with stage I or stage IIa colon cancer post resection from a single site in Taiwan.
During this study, 3 dose levels of Magicell-NK will be tested with a 3+3 design to determine the MTD/MFD: Cohort 1, low dose (2×10^8 cells), Cohort 2, middle dose (6×10^8 cells), and Cohort 3, high dose (12
18 ×10^8 cells).
100 项与 Magicell-NK(Medigen Biotechnology) 相关的临床结果
100 项与 Magicell-NK(Medigen Biotechnology) 相关的转化医学
100 项与 Magicell-NK(Medigen Biotechnology) 相关的专利(医药)
100 项与 Magicell-NK(Medigen Biotechnology) 相关的药物交易